Class summary at a glance.

Every drug in the Phosphodiesterase 5 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $228.0Mcombined across class
Total Rx claims: 1.8M563K unique beneficiaries
Generic mfrs (active): 59across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tadalafil

Brand: ADCIRCA · 628K Part D claims (CY24) · 192K beneficiaries · First FDA approval: 2003-11-26

28 generic mfrs 1057 plans require PA

Low NADAC$0.104

→

Avg plan cost$1.11

Part D spend $161.4M 11× spread, current vs floor

Class share

71%

of class CY24 spend

View profile →

Sildenafil

Brand: Revatio · 1.1M Part D claims (CY24) · 369K beneficiaries · First FDA approval: 1998-03-27

25 generic mfrs 359 plans require PA

Low NADAC$0.053

→

Avg plan cost$6.18

Part D spend $66.0M 117× spread, current vs floor

Class share

29%

of class CY24 spend

View profile →

Vardenafil

6K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2018-10-26

5 generic mfrs

Low NADAC$2.23

→

Avg plan cost$5.99

Part D spend $642093 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Avanafil

— Part D claims (CY24) · First FDA approval: 2024-06-14

1 generic mfrs

Low NADAC$42.14

→

Avg plan cost$42.14

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.